Protein post-translational modifications (PTMs) represent an untapped source of targets of huge biological interest and therapeutic potential. Their validation can only be indirect, because PTMs cannot be selectively hit by nucleic-acid based interference approaches. Here we describe the protocol for Post-translational Intracellular Silencing Antibody technology (P.I.S.A.), a method for the selection of intrabodies targeting the native acetylated version of proteins and their use for PTM-selective targeting and functional interference in living cells.
PISA screening protocol – A protocol for the selection of intracellular antibodies against post-translational modifications of native proteins
Michele Chirichella;Simonetta Lisi;Marco Fantini;Martina Goracci;Mariantonietta Calvello;Cristina Di Primio;Antonino Cattaneo
2017
Abstract
Protein post-translational modifications (PTMs) represent an untapped source of targets of huge biological interest and therapeutic potential. Their validation can only be indirect, because PTMs cannot be selectively hit by nucleic-acid based interference approaches. Here we describe the protocol for Post-translational Intracellular Silencing Antibody technology (P.I.S.A.), a method for the selection of intrabodies targeting the native acetylated version of proteins and their use for PTM-selective targeting and functional interference in living cells.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
